Document is current
Any future updates will be listed below
-
Authors
Ganguly, Koelina
Yamamoto, Keisuke https://orcid.org/0000-0002-6323-9540
Rodencal, Jason https://orcid.org/0000-0001-5637-611X
Encarnacion-Rosado, Joel https://orcid.org/0000-0002-0440-4278
Sohn, Albert S. W.
Biancur, Douglas E.
Lin, Elaine Y.
Wang, Ruohong https://orcid.org/0009-0003-9456-6514
Hirsch, Carolina Alcantara https://orcid.org/0000-0003-2193-362X
Sorrentino, Anthony
White, Elshaddai Z.
Grandgenett, Paul M.
Hollingsworth, Michael A. https://orcid.org/0000-0002-5255-8888
Kakiuchi, Miwako
Possemato, Richard https://orcid.org/0000-0002-2401-0030
Bar-Sagi, Dafna
Fujishiro, Mitsuhiro
Kimmelman, Alec C. https://orcid.org/0009-0002-9465-8411
- License Information
-
More Information
Article History
Received: 18 February 2024
Accepted: 17 August 2026
First Online: 23 September 2026
Ethics
Competing interests: A.C.K. is an inventor on patents pertaining to KRAS-regulated metabolic pathways; redox control pathways in pancreatic cancer; targeting GOT1 as a therapeutic approach; alanine import inhibition; and the autophagic control of iron metabolism. A.C.K. is on the scientific advisory board of Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals). E.Z.W. completed this work during his postdoctoral fellowship at NYU Grossman School of Medicine and is currently an employee of Merck Sharp & Dohme, a subsidiary of Merck; the opinions and perspectives expressed herein are those of the author (E.Z.W.) and do not represent the opinions or perspectives of his current employer. The remaining authors declare no competing interests.
